Accumetrics VerifyNow Aspirin AssayVerifyNow Aspirin Assay

Aspirin binds to the COX-1 enzyme to prevent the conversion of arachidonic acid to thromboxane A22, which result in platelet activation. The VerifyNow® Aspirin Assay utilizes arachidonic acid as the agonist to measure platelet function specifically along this pathway. Research shows that patients' response to aspirin varies1,2, and up to a quarter of patients are not responding adequately to its antiplatelet effects.3 These patients are 2-3 times more likely to have a major heart attack or stroke.3 The VerifyNow Aspirin Assay provides a simple measurement to determine whether or not a patient is responding to their aspirin therapy.

Additional Documentation

Instructions for Use, Aspirin Brochure (PDF), VerifyNow System (PDF) Interventional Cardiology Brochure (PDF),

INTENDED USE

The VerifyNow Aspirin Assay is a qualitative assay to aid in the detection of platelet dysfunction due to aspirin ingestion incitrated whole blood for the point of care or laboratory setting. This assay is not for use in patients with underlying congenital platelet abnormalities, patients with non-aspirin induced acquired platelet abnormalities or in patients receiving non-aspirin antiplatelet agents (may be used in patient s treated with selective COX-2 inhibitors, e.g., celecoxib (Celebrex®).

References:

  1. Lev EI et al. Aspirin and Clopidogrel Drug Response in Patients Undergoing Percutaneous Coronary Intervention. J Am Coll Cardiol 2006;47(1):27-33.
  2. Lee PY et al. Low-dose aspirin increases aspirin resistance in patients with coronary artery disease. Am J Med 2005;118(7):723-7.
  3. Gum PA et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41(6):961-5.